ArticleLife (Basel, Switzerland)2026
Stellate Ganglion Block Combined with Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss: A Retrospective Three-Arm Study.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sudden sensorineural hearing loss (SSNHL) carries unpredictable recovery, and adjunctive therapies beyond systemic corticosteroids are limited. Stellate ganglion block (SGB) and hyperbaric oxygen therapy (HBOT) have each been proposed as adjuncts, yet their combined effect remains poorly characterized. A retrospective three-arm cohort study (IRB No. 202401644B0) enrolled 75 SSNHL patients: Control (standard corticosteroid, n = 39), SGB (n = 21), and SGB+HBOT (n = 15). PTA4 improvement and Siegel recovery categories were assessed at two weeks, one month, and two months. Subgroup analyses stratified patients by baseline PTA4 < 70 dB and ≥70 dB. Groups differed significantly in overall baseline PTA4 (Kruskal-Wallis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.